برنيس لو، دكتوراه

Principal Investigator – Assistant Level
Immune Regulation and Tolerance Laboratory

blo (@) sidra.org

منشورات مختارة(equal contribution, *corresponding):

  • Cagdas D, Halaçlı SO, Tan Ç, Lo B, Çetinkaya PG, Esenboğa S, Karaatmaca B, Matthews H, Balcı-Hayta B, Arıkoğlu T, Ezgü F, Aladağ E, Saltık-Temizel İN, Demir H, Kuşkonmaz B, Okur V, Gümrük F, Göker H, Çetinkaya D, Boztuğ K, Lenardo M, Sanal Ö, Tezcan İ. “A Spectrum of Clinical Findings from ALPS to CVID: Several Novel LRBA Defects.” J Clin Immunol (2019) doi: 10.1007/s10875-019-00677-6.
  • Kiykim A, Ogulur I, Dursun E, Charbonnier LM, Nain E, Cekic S, Dogruel D, Karaca NE, Cogurlu MT, Bilir OA, Cansever M, Kapakli H, Baser D, Kasap N, Kutlug S, Altintas DU, Al-Shaibi A, Agrebi N, Kara M, Guven A, Somer A, Aydogmus C, Ayaz NA, Metin A, Aydogan M, Uncuoglu A, Patiroglu T, Yildiran A, Guner SN, Keles S, Reisli I, Aksu G, Kutukculer N, Kilic SS, Yilmaz M, Karakoc-Aydiner E, Lo B, Ozen A, Chatila TA, Baris S. “Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency.” J Allergy Clin Immunol Pract. (2019) .
  • Abdel-Motal UM, Al-Shaibi A, Elawad M, Lo B. “Zero tolerance! A perspective on monogenic disorders with defective regulatory T cells and IBD-like disease.” Immunol Rev. (2019) 287 (1):236-240.
  • Lo B, Abdel-Motal UM. “Lessons from CTLA-4 deficiency and checkpoint inhibition.” Curr Opin Immunol (2017) 49:14-19.
  • Lo B, Fritz JM, Su HC, Uzel G, Jordan MB, Lenardo MJ. “CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency.” Blood(2016) 128(8): 1037-42.
  • Lenardo M,Lo B, Lucas CL. “Genomics of Immune Diseases and New Therapies.” Annu Rev Immunol (2016) 20;34:121-49.
  • LoB*, ZhangK*, Lu W, Zheng L, Zhang Q, Kanellopoulou C, Zhang Y, Liu Z, Fritz JM, MarshR, HusamiA, KissellD, NortmanS, ChaturvediV, HainesH, YoungLR, MoJ, FilipovichAH, Bleesing JJ, Mustillo P, Stephens M, Rueda CM, Chougnet CA, Hoebe K, McElweeJ, HughesJD, Karakoc-Aydiner E, MatthewsHF, PriceS, Su HC, RaoVK, LenardoMJ, Jordan MB. “Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.” Science.(2015) 349(6246):436-40.
  • Kuehn HS*, Ouyang W*, Lo B*, Deenick EK, Niemela JE, Avery DT, Schickel JN, Tran DQ, Stoddard J, Zhang Y, Frucht DM, Dumitriu B, Scheinberg P, Folio LR, Frein CA, Price S, Koh C, Heller T, Seroogy CM, Huttenlocher A, Rao VK, Su HC, Kleiner D, Notarangelo LD, Rampertaap Y, Olivier KN, McElwee J, Hughes J, Pittaluga S, Oliveira JB, Meffre E, Fleisher TA, Holland SM,Lenardo MJ, Tangye SG, Uzel G. “Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.” Science(2014) 345(6204):1623-7.
  • Price S, Shaw PA, Seitz A, Joshi G, Davis J, Niemela JE, Perkins K, Hornung RL, Folio L, Rosenberg PS, Puck JM, Hsu AP, Lo B, Pittaluga S, Jaffe ES, Fleisher TA, Rao VK, Lenardo MJ. “Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations.” Blood(2014) 123 (13):1989-99.
  • Lo B, Hansen S, Evans K, Heath JK, and Wright JR. “Alveolar epithelial type II cells induce T cell tolerance to specific antigen.” J Immunol(2008) 180: 881-888.